Drugmaker Pfizer is warning doctors that it expects to run low on supplies of Bicillin L-A, a long-acting injection of the ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

Zohran Mamdani told a group of top business leaders in New York City on Tuesday that he would discourage the use of the ...

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

Last month, during Cannes Lions, Netflix announced that its ad inventory will be available to buy programmatically via Yahoo ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to maplirpacept’s safety or efficacy.

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. has initiated a new clinical study titled A Phase 1, ...